Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3209-3214

  Fuleihan, Ghada El Hajj ^a   Salamoun, Mariana ^a   Mourad, Yasser Abou ^a   Chehal, Aref ^a   Salem, Ziad ^a   Mahfoud, Ziyad ^a   Shamseddine, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOCHEMICAL MARKER; CALCIUM; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; VITAMIN D; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL;

ADULT; AMENORRHEA; ARTICLE; BONE MINERAL; BONE REMODELING; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HIP; HUMAN; HYPOCALCEMIA; LUMBAR SPINE; MONITORING; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINE; BLOOD; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CALCIFEDIOL; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NEOPLASM STAGING; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; PREMENOPAUSE; TAMOXIFEN;

EID: 21244494910     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2004-1444     Document Type: Article

References (30)

1. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, Edwards BK 1996 Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:1571-1579
2. Smart CR, Byrne C, Smith RA, Garfinkel L, Letton AH, Dodd GD, Beahrs OH 1997 Twenty year follow-up of the breast cancers diagnosed during the Breast-Cancer Demonstration Project. CA Cancer J Clin 47:134-149
3. Ganz PA, Greendale GA 2001 Menopause and breast cancer: addressing the secondary health effects of adjuvant chemotherapy. J Clin Oncol 19:3303-3305
4. Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN 1998 Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16:6-11
5. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I 1997 Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluoracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347
6. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo controlled study. J Clin Oncol 15:955-962
7. Shapiro CL, Manola J, LeBoff MS 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with premenopausal early-stage breast cancer. J Clin Oncol 19:3306-3311
8. Shamseddine A, Sibai AM, Gehchan N, Rahal B, El-Saghir N, Ghosn M, Aftimos G, Chamsuddine N, Seoud M, For The Lebanese Cancer Epidemiology Group 2004 Cancer incidence in post-war Lebanon: findings from the first national population-based registry. Ann Epidemiol 14:663-668
9. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C 2001 Long term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378
10. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT 1989 Comparison of the three intravenous bisphosphonates in cancerassociated hypercalcemia. Lancet 2:1180-1182
11. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized controlled trials. J Clin Oncol 19:558-567
12. Younis H, Farhat G, El-Hajj Fuleihan G 2002 Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Dens 5:1-7
13. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
14. El-Hajj Fuleihan G, Baddoura R, Awada H, Salam N, Salamoun M, Rizk P 2002 Low peak bone mineral density in healthy Lebanese subjects. Bone 31:520-528
15. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C 1994 Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 10:1503-1514
16. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston Jr CC, Lindsay R 1998 Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489
17. Fuleihan GE, Testa MA, Angell JE, Porrino N, Leboff MS 1995 Reproducibility of DXA densitometry: a model for bone loss estimates. J Bone Miner Res 10:1004-1014
18. Reichman BS, Green KB 1994 Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 16:125-129
19. Reyno LM, Levine MN, Skingley P, Arnold A, Abu Zahra H 1992 Chemotherapy induced amenorrhea in a randomized trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer 29A:21-23
20. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J 1998 Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708
21. Fogelman I, Blake GM, Blamey R, Palmer M, Sallerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W 2003 Bone mineral density in premenopausal women treated for node positive breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Osteoporos Int 14:1001-1006
22. Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
23. Saarto T, Blomqvist C, Virkknnen, Elomaa 2001 Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17
24. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L 2002 Randomized, placebocontrolled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219:3224
25. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
26. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal events in patients with multiple myeloma. N Engl J Med 334:488-493
27. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Eng J Med 326:852-856
28. Catherino WH, Jordan VC 1993 A risk benefit of tamoxifen therapy. Drug Safety 8:381-387
29. Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C 2002 Mechanism of circadian variation in bone resorption. Bone 30:307-313
30. Coleman RE 2003 Current and future status of adjuvant therapy for breast cancer. Cancer 97 (Suppl 3):880-886